SecBot SecBot

PFE

PFIZER INC
NYSE· Pharmaceutical Preparations· Inc. DE· CIK 0000078003 Biotech & Drug Discovery
$28.88 −0.01 (−0.03%)
Nov 16 4:00 PM ET · prev $28.89
Market cap
$164.4B
Large cap
Consensus
Hold
38% Buy or better · 34 analysts
Median target
$30.00
+4% · range $25.00–37.00
1 year
+15.2%
from $25.08 · Nov 17
30 days
−2.4%
from $29.58
52-week range
$23.67–30.79
−6% from high · low Jun 25
Avg volume 20D
34.98M
shares / day
Short interest
134.42M
≈2.4% of shares · −2.5%
Days to cover
4.6
at average volume
Insider net
+$2.8M
3 buyers · 1 seller · since Mar 27
New fund stakes
2
Q2 2026 13F · 3 exits
Reddit crowd
53°
Neutral · 16 mentions this week
SecBot read BULLISH 4 reports · 90 days
Balance 0 bearish · 1 bullish · 1 mixed · 2 neutral oldest → newest, height = score
Avg score ·High conf. 3/4

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBULLISH

    3 insiders bought $3.0M at an average $25.77. 1 insider sold $134.7K. Price is 12% above their cost.

  • InstitutionsMIXED

    Q2 2026: 47 added (2 new), 36 trimmed or exited. Largest new: Tudor Investment Et Al $16.8M.

  • AnalystsMIXED

    13 of 34 rate it Buy or better. Median target $30.00 (+4%).

  • Short sellersSTEADY

    Short interest −2.5% to 134.42M shares. 4.6 days to cover, ≈2.4% of shares.

  • TrendUPTREND

    0% above its 50-day average.

  • SocialQUIET

    Crowd 53° (neutral) this week from 16 mentions: 2 bullish, 1 bearish. No setup is alerting. Excludes 1 subscriber-only day.

Who's buying

13F· Q2 2026
2
new positions
3
exits
$16.8M
in new stakes · top 1 shown
FundMoveSharesValue
WELLINGTON MANAGEMENT GROUP LLPTRIM27,826,078$670.1M
CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEMADD17,261,993$415.7M
AMERIPRISE FINANCIAL INCTRIM14,364,565$345.9M
Assenagon Asset Management S.A.ADD11,902,374$286.6M
VICTORY CAPITAL MANAGEMENT INCTRIM9,152,541$220.4M
PRUDENTIAL FINANCIAL INCADD7,718,545$185.9M
SUSQUEHANNA INTERNATIONAL GROUP, LLPDOUBLED6,547,246$157.7M
D. E. Shaw & Co., Inc.TRIM5,414,297$130.4M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

34 analysts
Hold 38% rate it Buy or better
Strong Buy5Buy8Hold18Sell2Strong Sell1
12-month targets · 26 analysts

Price is inside the target range. Median implies +4%.Targets as of Nov 16, 2026.

Recent actions
DateFirmActionRating
Nov 6, 2026Freedom Broker
MAINTAIN
MAINTAINBuy
Nov 5, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Nov 4, 2026UBS
MAINTAIN
MAINTAINNeutral
Nov 4, 2026Scotiabank
MAINTAIN
MAINTAINSector Outperform
Nov 4, 2026Citigroup
MAINTAIN
MAINTAINNeutral
Nov 4, 2026RBC Capital
MAINTAIN
MAINTAINSector Perform
Congressional trades
PFE trades disclosed by members of Congress, with disclosure delay.
6 members · 8 buys / 6 sells
DateMemberType AmountDisclosed
Oct 7, 2026 Ro KhannaDHouse Spouse account · Pfizer Inc BUY $15K–$50K Nov 5, 2026 +29d
Sep 25, 2026 Ro KhannaDHouse Spouse account · Pfizer Inc BUY $1K–$15K Oct 7, 2026 +12d
Sep 11, 2026 Ro KhannaDHouse Child account · Pfizer Inc BUY $1K–$15K Oct 7, 2026 +26d
Sep 4, 2026 Ro KhannaDHouse Spouse account · Pfizer Inc SELL $15K–$50K Oct 7, 2026 +33d
Jul 7, 2026 Ro KhannaDHouse Child account · Pfizer Inc BUY $1K–$15K Aug 7, 2026 +31d
Jun 8, 2026 Tommy TubervilleRSenate Joint account · Pfizer Inc SELL $15K–$50K Jul 16, 2026 +38d
May 15, 2026 Ro KhannaDHouse Spouse account · Pfizer Inc BUY $1K–$15K Jun 9, 2026 +25d
Apr 13, 2026 Ro KhannaDHouse Spouse account · Pfizer Inc BUY $1K–$15K May 11, 2026 +28d
Mar 13, 2026 Gilbert CisnerosDHouse Pfizer Inc SELL $1K–$15K Apr 7, 2026 +25d
Feb 10, 2026 Gilbert CisnerosDHouse Pfizer Inc BUY $1K–$15K Mar 9, 2026 +27d

Insider ledger

Form 4
$3.0M
bought · 3 insiders
$134.7K
sold · 1 insider
+12.1%
vs their $25.77 cost
DateInsiderTypeValue
Oct 30, 2026
BOURLA ALBERT
Chairman & CEO
Oct 30, 2026
AWARD$610.40
Oct 15, 2026
BOURLA ALBERT
Chairman & CEO
Oct 15, 2026
AWARD$588.80
Oct 13, 2026
BOURLA ALBERT
Chairman & CEO
Oct 13, 2026
AWARD$2.0K
Sep 30, 2026
BOURLA ALBERT
Chairman & CEO
Sep 30, 2026
AWARD$598.92
Sep 25, 2026
SMITH JAMES C
Director
Sep 25, 2026
AWARD$45.0K
Sep 25, 2026
Taraporevala Cyrus
Director
Sep 25, 2026
AWARD$37.5K
Sep 25, 2026
NARAYEN SHANTANU
Director
Sep 25, 2026
AWARD$50.0K
Sep 25, 2026
Quincey James
Director
Sep 25, 2026
AWARD$38.7K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
34 drugs tracked · Drug pipeline →
Recent

Washington

Corporate Lobbying

114 lobbying filings and 12 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
134,422,620
shares short
-2.5%
vs prior settlement
4.6
days to cover
≈2.4%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 8, 2026 Clinical trial readout
T-90d Trial Readout: disitamab vedotin (Phase 3)
Trial: Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cance
Nov 9, 2026 Event
MARCAINE WITH EPINEPHRINE
Limited Availability: Limited Supply Available. Next Delivery: January 2027; Estimated Recovery: Mar
Nov 3, 2026 SEC
Pfizer announced the permanent appointment of Cecile Guegan as CFO and Executive Vice President, effective November 1…
8-K · Impact 2/10
Nov 3, 2026 SEC
Pfizer reported Q3 2026 adjusted diluted EPS of $0.87, beating the $0.73 consensus by 19.2%, on revenue of $16.58B…
8-K · Impact 6/10
Oct 30, 2026 SEC
The District of New Jersey granted Pfizer's motions to dismiss a former employee's retaliation and discrimination…
COURT-RULING · Impact 2/10
Oct 30, 2026 Insider
BOURLA ALBERT was granted 20 shares
Chairman & CEO @ $30.52 ($610.40)
Oct 30, 2026 Event
NIETO v. PFIZER, INC. et al
Court ruling (njd). Docket: 2:25-cv-18265
Oct 15, 2026 Insider
BOURLA ALBERT was granted 20 shares
Chairman & CEO @ $29.44 ($588.80)
Reddit Mentions per day, 14 days
Crowd this week 53° Neutral 2 bullish · 1 bearish
Mentions, 7 days 16 2 in posts · 14 in comments
Recent posts
Recent comments
All social signals and their track records

SecBot reports

21 filings · 7 bullish · 2 bearish · 1 mixed · 11 neutral
All PFE filing & press-release reports (21)